A lawsuit was filed on behalf of investors in Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) shares over alleged securities laws violations.
San Diego, CA -- (SBWIRE) -- 02/20/2018 -- An investor, who purchased shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM), filed a lawsuit in over alleged Securities Laws violations by Bellicum Pharmaceuticals Inc.
Investors who purchased shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
On January 30, 2018, post-market, Bellicum Pharmaceuticals Inc announced "that the Company has received notice from the U.S. Food and Drug Administration (FDA) that U.S. studies of BPX-501", Bellicum Pharmaceuticals Inc's lead product candidate, "have been placed on a clinical hold following three cases of encephalopathy deemed as possibly related to BPX-501." Shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) declined to as low as $5.42 per share on February 6, 2018.
The plaintiff claims that between May 8, 2017, and January 30, 2018, the Defendants made false and/or misleading statements and/or failed to disclose that a substantial undisclosed risk of encephalopathy was associated with the Company's lead product candidate BPX-501, and that as a result of the foregoing, Bellicum's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels